vs
Side-by-side financial comparison of Clearwater Paper Corp (CLW) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Clearwater Paper Corp is the larger business by last-quarter revenue ($360.3M vs $346.4M, roughly 1.0× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs -3.6%, a 31.6% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -4.7%). Over the past eight quarters, Clearwater Paper Corp's revenue compounded faster (2.3% CAGR vs 1.5%).
Clearwater Paper Corporation is an American pulp and paperboard manufacturer. The company was created on December 9, 2008, via a spin-off from Potlatch Corporation and is headquartered in Spokane, Washington.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CLW vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.3M | $346.4M |
| Net Profit | $-12.8M | $97.3M |
| Gross Margin | -0.2% | 57.2% |
| Operating Margin | — | 36.1% |
| Net Margin | -3.6% | 28.1% |
| Revenue YoY | -4.7% | 4.8% |
| Net Profit YoY | -103.2% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $360.3M | $346.4M | ||
| Q4 25 | $386.4M | $339.0M | ||
| Q3 25 | $399.0M | $327.3M | ||
| Q2 25 | $391.8M | $321.4M | ||
| Q1 25 | $378.2M | $330.6M | ||
| Q4 24 | $387.1M | $348.5M | ||
| Q3 24 | $393.3M | $345.5M | ||
| Q2 24 | $344.4M | $336.2M |
| Q1 26 | $-12.8M | $97.3M | ||
| Q4 25 | $38.3M | $44.7M | ||
| Q3 25 | $-53.3M | $38.7M | ||
| Q2 25 | $2.7M | $34.0M | ||
| Q1 25 | $-6.3M | $58.0M | ||
| Q4 24 | $199.1M | $37.5M | ||
| Q3 24 | $5.8M | $33.8M | ||
| Q2 24 | $-25.8M | $38.4M |
| Q1 26 | -0.2% | 57.2% | ||
| Q4 25 | 4.5% | 59.7% | ||
| Q3 25 | 4.7% | 59.5% | ||
| Q2 25 | 11.0% | 59.8% | ||
| Q1 25 | 9.7% | 58.4% | ||
| Q4 24 | 3.8% | 55.5% | ||
| Q3 24 | 7.7% | 54.2% | ||
| Q2 24 | -0.6% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 1.9% | 19.9% | ||
| Q3 25 | -13.9% | 17.9% | ||
| Q2 25 | 2.5% | 16.8% | ||
| Q1 25 | -1.1% | 21.6% | ||
| Q4 24 | -4.0% | 16.9% | ||
| Q3 24 | -0.3% | 15.0% | ||
| Q2 24 | -13.6% | 11.8% |
| Q1 26 | -3.6% | 28.1% | ||
| Q4 25 | 9.9% | 13.2% | ||
| Q3 25 | -13.4% | 11.8% | ||
| Q2 25 | 0.7% | 10.6% | ||
| Q1 25 | -1.7% | 17.5% | ||
| Q4 24 | 51.4% | 10.8% | ||
| Q3 24 | 1.5% | 9.8% | ||
| Q2 24 | -7.5% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $2.36 | $0.95 | ||
| Q3 25 | $-3.30 | $0.81 | ||
| Q2 25 | $0.17 | $0.70 | ||
| Q1 25 | $-0.38 | $1.17 | ||
| Q4 24 | $11.87 | $0.74 | ||
| Q3 24 | $0.35 | $0.66 | ||
| Q2 24 | $-1.55 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.5M | $245.4M |
| Total DebtLower is stronger | $361.1M | $1.2B |
| Stockholders' EquityBook value | $813.8M | $796.3M |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | 0.44× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $36.5M | $245.4M | ||
| Q4 25 | $30.7M | $363.4M | ||
| Q3 25 | $34.4M | $296.4M | ||
| Q2 25 | $46.7M | $292.9M | ||
| Q1 25 | $44.0M | $306.8M | ||
| Q4 24 | $79.6M | $320.8M | ||
| Q3 24 | $35.5M | $299.3M | ||
| Q2 24 | $39.6M | $344.4M |
| Q1 26 | $361.1M | $1.2B | ||
| Q4 25 | $346.8M | $1.2B | ||
| Q3 25 | $337.0M | $1.2B | ||
| Q2 25 | $330.1M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $283.4M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | $813.8M | $796.3M | ||
| Q4 25 | $825.3M | $911.5M | ||
| Q3 25 | $783.0M | $849.2M | ||
| Q2 25 | $836.8M | $882.3M | ||
| Q1 25 | $836.6M | $820.8M | ||
| Q4 24 | $854.6M | $906.9M | ||
| Q3 24 | $664.6M | $878.9M | ||
| Q2 24 | $658.6M | $905.4M |
| Q1 26 | $1.6B | $2.4B | ||
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.6B | $2.4B | ||
| Q2 25 | $1.6B | $2.5B | ||
| Q1 25 | $1.6B | $2.5B | ||
| Q4 24 | $1.7B | $2.5B | ||
| Q3 24 | $2.5B | $2.5B | ||
| Q2 24 | $2.5B | $2.5B |
| Q1 26 | 0.44× | 1.53× | ||
| Q4 25 | 0.42× | 1.34× | ||
| Q3 25 | 0.43× | 1.44× | ||
| Q2 25 | 0.39× | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | — | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $5.0M | $93.6M | ||
| Q3 25 | $34.0M | $111.3M | ||
| Q2 25 | $-28.2M | $17.4M | ||
| Q1 25 | $1.5M | $116.6M | ||
| Q4 24 | $-35.1M | $43.8M | ||
| Q3 24 | $16.2M | $48.8M | ||
| Q2 24 | $21.1M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $-9.9M | $87.2M | ||
| Q3 25 | $15.7M | $106.3M | ||
| Q2 25 | $-51.1M | $13.6M | ||
| Q1 25 | $-31.2M | $100.9M | ||
| Q4 24 | $-68.1M | $35.2M | ||
| Q3 24 | $-30.8M | $39.4M | ||
| Q2 24 | $3.0M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | -2.6% | 25.7% | ||
| Q3 25 | 3.9% | 32.5% | ||
| Q2 25 | -13.0% | 4.2% | ||
| Q1 25 | -8.2% | 30.5% | ||
| Q4 24 | -17.6% | 10.1% | ||
| Q3 24 | -7.8% | 11.4% | ||
| Q2 24 | 0.9% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 3.9% | 1.9% | ||
| Q3 25 | 4.6% | 1.5% | ||
| Q2 25 | 5.8% | 1.2% | ||
| Q1 25 | 8.6% | 4.7% | ||
| Q4 24 | 8.5% | 2.5% | ||
| Q3 24 | 12.0% | 2.7% | ||
| Q2 24 | 5.3% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 0.13× | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | -10.44× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | -0.18× | 1.17× | ||
| Q3 24 | 2.79× | 1.44× | ||
| Q2 24 | — | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLW
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
